Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.
about
The potential for emerging therapeutic options for Clostridium difficile infectionAntimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection[Current data and trends on the development of antibiotic resistance of Clostridium difficile].Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection.The magnitude and duration of Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort studyThe history of the tetracyclines.Clostridium difficile and the microbiotaBeneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile InfectionEffect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of miceEffects of tigecycline and vancomycin administration on established Clostridium difficile infection.Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infectionClostridium difficile: improving the prevention paradigm in healthcare settings.The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection.Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strainsDo piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization?Models for the study of Clostridium difficile infection.Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.Clinical update for the diagnosis and treatment of Clostridium difficile infection.IMPACT OF TIGECYCLINE VERSUS OTHER ANTIBIOTICS ON THE FECAL METABOLOME AND ON COLONIZATION RESISTANCE TO CLOSTRIDIUM DIFFICILE IN MICE.Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.Current state of Clostridium difficile treatment options.Therapy of Clostridium difficile infection: perspectives on a changing paradigm.Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin.Novel Antimicrobials for the Treatment of Clostridium difficile Infection.
P2860
Q28082059-A8D742C7-DE40-40B2-AC20-624354D95D70Q28084026-325CFE61-52D1-433B-9704-79334F0944C7Q30575525-8985F2F4-187B-480E-85E0-7466EA9634E4Q33728333-2808D363-DC0D-4354-8C94-31FBE111E17DQ34089890-E1D90242-3304-40B8-AD45-FE46FEDD4A5DQ34242314-0CE6FD65-CE67-4677-95CD-41F4021EB819Q34311594-6BEE69CA-4CB6-4FAA-B75A-90DEE81ADEE5Q34597557-95B4A431-55BF-4BFA-8D50-18970722B61BQ34726133-596BD495-6BBE-4CBB-A986-0AC87A4BDC7BQ34932729-A9D34A5C-9677-4EDD-9965-DBB808FB086BQ35076948-2215384D-9A01-42B9-9C07-465E18C49A12Q35109773-B1C030DF-85FF-419D-97C8-FC4EE286A96AQ35222472-2148128F-8F96-4280-BD90-E51519C8624EQ35577842-C92FB0A1-80FA-4B0E-8DC8-4035792805ABQ35914081-5D3198CB-8F95-4EB4-96D1-E258556F42A9Q35993212-F52A5D80-094A-4266-B2D7-1BA5C6E31CDAQ36019356-64564D73-8C81-4927-9368-B86E3F91F65CQ36683574-37F84375-CAC6-4366-BAD0-EA72479D8318Q37633859-E8F2B534-6A9D-477F-86A0-34E33C546040Q37649756-C568F8C6-0489-4552-A8AA-1DCF006E3AC5Q37955156-1010B396-9001-4EBF-8C86-FFA362F048FEQ38023283-D57CB629-D58A-466B-A0DF-64BBF7137B6FQ38139991-4CF62AB6-FD9B-4420-AE92-5810510EDB58Q41983988-C7223689-410E-46A8-AB15-FB1E1D379187Q55405974-10748934-BC04-4674-88B9-A7E1B75A5A12
P2860
Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@ast
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@en
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@nl
type
label
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@ast
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@en
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@nl
prefLabel
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@ast
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@en
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@nl
P2093
P2860
P356
P1476
Tigecycline exhibits inhibitor ...... te growth or toxin production.
@en
P2093
Georgios Kypriotakis
Michael J Pultz
Robin L P Jump
P2860
P304
P356
10.1128/AAC.00839-10
P407
P577
2010-12-06T00:00:00Z